<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972383</url>
  </required_header>
  <id_info>
    <org_study_id>KMUHIRB-F(II)-20170062</org_study_id>
    <nct_id>NCT04972383</nct_id>
  </id_info>
  <brief_title>Comparing Effect of Autologous Platelet-Rich Plasma Versus Hyaluronic Acid Treatment on Knee Osteoarthritis</brief_title>
  <official_title>A Prospective,Double-Blind Randomized Controlled Trial Comparing Effect of Autologous Platelet-Rich Plasma Versus Hyaluronic Acid Treatment on Progression of Structural Changes in Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and structural change of intraarticular single platelet-rich&#xD;
      plasma(PRP) versus novel crosslinked Hyaluronic Acid(HA)(HyajointPlus) for the treatment of&#xD;
      early stage knee osteoarthritis(OA). This was a prospective, double-blind, RCT with an&#xD;
      allocation ratio of 1:1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the PRP group, an Aeon Acti-PRP set was used and an approximately 4-mL PRP volume was&#xD;
      yielded and was used in a single-dose treatment. In the HA group, HYAJOINT Plus containing 60&#xD;
      mg of purified sodium hyaluronate was used in a single-dose treatment. All PRP and HA&#xD;
      injection syringes were covered with opaque envelop, and the intra-articular injection&#xD;
      procedure was performed by the same physician without ultrasound or other imaging guidance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2017</start_date>
  <completion_date type="Actual">October 16, 2019</completion_date>
  <primary_completion_date type="Actual">October 16, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of Western Ontario and McMaster Universities Index (WOMAC) score from baseline</measure>
    <time_frame>Baseline and 1-month, 3-month, 6-month after injection</time_frame>
    <description>The minimum value of Western Ontario and McMaster Universities Index (WOMAC) score is zero and the maximum is 96, whether higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of Knee Cartilage Grading System from baseline</measure>
    <time_frame>Baseline and 1-month, 3-month, 6-month after injection</time_frame>
    <description>The Cartilage Grading System classifies the cartilage from grades 0 to 6 according to parameters of sharpness, clarity and thickness change of the cartilage band. Grade 0 refers to normal and healthy cartilage, while grade 6 refers to severely eroded cartilage, whether higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Platelet Rich Plasma group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single injection platelet rich plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic Acid group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single injection of hyaluronic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Platelet Rich Plasma</intervention_name>
    <description>In the Platelet Rich Plasma group, 4mL Platelet Rich Plasma was given.</description>
    <arm_group_label>Platelet Rich Plasma group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Hyaluronic Acid</intervention_name>
    <description>In the Hyaluronic group, 3mLHYAJOINT Plus was given.</description>
    <arm_group_label>Hyaluronic Acid group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients older than 50 years&#xD;
&#xD;
          2. a diagnosis of primary knee osteoarthritis&#xD;
&#xD;
          3. Kellgren-Lawrence (K-L) grading scale smaller than 3&#xD;
&#xD;
          4. both male and female.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients younger than 50 years of age&#xD;
&#xD;
          2. K-L grade 3 or more&#xD;
&#xD;
          3. history or active presence of clinically significant inflammatory articular or&#xD;
             rheumatic disease other than OA&#xD;
&#xD;
          4. generalized OA&#xD;
&#xD;
          5. the detection of rapidly progressive OA before the start of the trial&#xD;
&#xD;
          6. underwent any previous lower extremity surgery&#xD;
&#xD;
          7. excessive mechanical axis deviation (varus &gt; 5°, valgus &gt; 5°)&#xD;
&#xD;
          8. body mass index larger than 30&#xD;
&#xD;
          9. history or presence of malignant disorders&#xD;
&#xD;
         10. systemic disorders such as diabetes mellitus, severe cardiovascular diseases,&#xD;
             hematologic diseases, immune-deficiencies, and infections&#xD;
&#xD;
         11. systematic or intra-articular corticosteroid therapy in the previous 3 months&#xD;
&#xD;
         12. prior treatment with HA in the past 6 months&#xD;
&#xD;
         13. anticoagulants or antiaggregants therapy in the preceding 30 days&#xD;
&#xD;
         14. non-steroidal anti-inflammatory medications in the preceding 7 days&#xD;
&#xD;
         15. platelet count less than 150,000/ml of blood&#xD;
&#xD;
         16. hemoglobin values less than 12g/dL of blood.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsuan-Ti Huang, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Kaohsiung Medical University, Orthopedics Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>starting 12 months after publication</ipd_time_frame>
    <ipd_access_criteria>Studies involving platelet rich plasma, hyaluronic acid can contact us for additional information.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

